Literature DB >> 16924997

Efficacy of EMLA cream to reduce fear and pain associated with interferon beta-1a injection in patients with multiple sclerosis.

Marijean Buhse1.   

Abstract

Fear of pain from injections may affect adherence to needed drug therapy. A single-blind, placebo-controlled crossover study was conducted to evaluate the efficacy of EMLA cream in reducing the fear and pain associated with intramuscular (IM) injection during administration of interferon beta-1a to patients with multiple sclerosis. Patients rated fear of injection on a visual analog scale before the injection and rated injection pain following the injection. With the application of EMLA cream, the mean pain-of-injection score was found to be significantly lower than the mean fear-of-injection score. The 18 patients who completed the study experienced a statistically significant decrease in both scores. This study suggests that the use of EMLA cream may reduce the pain and fear associated with IM injections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16924997     DOI: 10.1097/01376517-200608000-00004

Source DB:  PubMed          Journal:  J Neurosci Nurs        ISSN: 0888-0395            Impact factor:   1.230


  4 in total

1.  Facilitating medication adherence in patients with multiple sclerosis.

Authors:  Gina Remington; Yolanda Rodriguez; Diana Logan; Caroline Williamson; Katherine Treadaway
Journal:  Int J MS Care       Date:  2013

Review 2.  Current management of pain associated with multiple sclerosis.

Authors:  Walter Pöllmann; Wolfgang Feneberg
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  A Topical Adhesive Containing Anesthetic and Heating Components to Reduce Injection Pain with Subcutaneous Multiple Sclerosis Medications: A Pilot Study.

Authors:  Theodore R Brown; Virginia I Simnad
Journal:  Int J MS Care       Date:  2017 Mar-Apr

4.  An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.

Authors:  J Theodore Phillips; Edward Fox; William Grainger; Dianne Tuccillo; Shifang Liu; Aaron Deykin
Journal:  BMC Neurol       Date:  2011-10-14       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.